Skip to search formSkip to main contentSkip to account menu

Mopidamol

Known as: 2,2',2",2"'-[[4-(1-Piperidinyl)pyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilo]tetrakisethanol, 2,2',2",2"'-[(4-Piperidinopyrimido[5,4-d-]pyrimidine-2,6-diyl)dinitrilo]tetraethanol, Mopidamol [Chemical/Ingredient] 
A phosphodiesterase inhibitor which inhibits platelet aggregation. Formerly used as an antineoplastic.
National Institutes of Health

Related topics

Related topics

10 relations

Broader (1)

Antineoplastic Agents
In Bloodagonistsanalogs & derivativesantagonists & inhibitors

Narrower (2)

RA-233Rapenton

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Mopidamol.
A derivative of dipyridamole that is a phosphodiesterase inhibitor, with potential antiplatelet activity. Mopidamol inhibits the… 
1996
1996
Inhibition of ferrous-induced lipid peroxidation by dipyridamole, RA-642 and mopidamol in human lung tissue.
1996
1996
The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
1994
1994
The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats.
We assessed the effect of dipyridamole, RA-642 and mopidamol, on lenticular opacities in a model of experimental diabetic… 
1991
1991
The pyrimido-pyrimidine derivative RA-642: a potent inhibitor of ferrous-induced lipid peroxidation in cell membranes.
The effects of three pyrimido-pyrimidine derivatives (RA-642, dipyridamole and mopidamol) on hydroxyl anion-induced lipid… 
1989
1989
Inhibition of phosphoribosylpyrophosphate synthetase by 4-methoxy-(MRPP) and 4-amino-8-(D-ribofuranosylamino) pyrimido[5,4-d]pyrimidine (ARPP).
1989
1989
[Adjuvant therapy of non-small cell bronchial cancer with mopidamol].
Between January 1982 and April 1986 a double-blind randomized placebo controlled study of mopidamol, employed as adjunct therapy… 
Highly Cited
1988
Highly Cited
1988
Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188.
Mopidamol (RA-233), a derivative of dipyridamole, is a phosphodiesterase inhibitor that has been shown previously to limit… 
1988
1988
Mopidamol in non-small cell lung cancer: anti-oncogene or accident?
The paper by Zacharski et al. in this issue is both provoca-tive and puzzling. Mopidamol (RA-233), an antiplatelet drug related… 
1987
1987
Polymeric inhibitors of platelet aggregation. II. Copolymers of dipyridamole and related drugs with N-vinylpyrrolidone.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)